BIO-key International (BKYI) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
14 Aug, 2026Executive summary
Q2 2026 revenue increased 13% year-over-year to $1.92M, driven by a 53% rise in license fees and expanding EMEA opportunities, while net loss improved by 51% to $(577K); H1 net loss improved nearly 60% on 23% revenue growth, though results missed expectations due to delayed hardware shipments now expected in H2.
Strong momentum in EMEA with new deals, channel partners, and project discussions accelerating, supported by favorable market trends and regulatory frameworks; notable wins include national initiatives in Jordan, Portugal, Saudi Arabia, and a U.S. credit union deployment, with expanding opportunities in government, defense, financial services, and education.
Completed a 1-for-10 reverse stock split, regained Nasdaq compliance, and raised $2.5M in new capital to support growth and listing requirements.
Strategic focus on growing recurring revenue, expanding channel partnerships, and pursuing selective acquisitions in the IAM space, with increased demand for MFA and biometrics due to remote work and cybersecurity trends.
Financial highlights
Q2 2026 revenue rose 13% year-over-year to $1.92M, driven by a 53% increase in license fee revenue; hardware revenue fell 19% and service revenue dropped 28% due to timing and non-recurring items.
Gross profit increased to $1.7M, with gross margin improving to 87% from 73%, reflecting higher license revenue and sales of fully reserved inventory.
Operating expenses decreased 5% to $2.2M, mainly from cost containment, offset by one-time reverse split and audit costs.
Q2 net loss improved to $577K ($0.56/share) from $1.17M ($2.01/share) year-over-year; H1 net loss improved 59% to $782K ($0.75/share).
For the six months ended June 30, 2026, revenue grew 23% to $4.07M, with license fees up 36% and hardware up 23%.
Outlook and guidance
Targeting continued revenue growth and profitability in H2 2026, with large hardware and software orders expected to close and robust pipeline in regulated industries.
Strategic focus on AI governance and leveraging biometric authentication in AI security, with expansion in EMEA and new projects in government and financial sectors.
Confident in maintaining high gross margins (85% range) and stable or declining expenses.
Liquidity remains a concern; additional financing or improved cash flow from operations is needed to sustain operations over the next twelve months.
Latest events from BIO-key International
- Shareholders are asked to approve warrant-related share issuance that could dilute ownership by 53.2%.BKYI
Proxy filing - Biometric IAM solutions see rapid growth, regulatory tailwinds, and a path to profitability in 2026.BKYI
Investor presentation - Proxy covers director elections, auditor change, executive pay, and governance practices.BKYI
Proxy filing - Biometric authentication growth accelerates amid regulatory demand and sustained profitability.BKYI
RedChip Future Tech Investor Conference - Q1 revenue up 34% to $2.15M; profitability and Nasdaq relisting remain key near-term issues.BKYI
Q1 2026 - 2025 revenue fell 12%, but strong Q1 2026 outlook and sector wins support 2026 growth.BKYI
Q4 2025 - Vote proposed on a reverse stock split to regain Nasdaq compliance and enhance stock value.BKYI
Proxy Filing - Vote on a reverse stock split to regain Nasdaq compliance and enhance stock marketability.BKYI
Proxy Filing - Q1 2025 saw sequential revenue growth, margin strength, and improved cash, but liquidity risks remain.BKYI
Q1 2025